Formulary Focus: Cosentyx Navigating Tightly Managed Psoriasis Market

Payers’ prior authorization and step therapy requirements may delay broad access to Novartis’ Cosentyx until after competition arrives in 2016 from Lilly’s IL-17 inhibitor and possibly from a biosimilar to Humira.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America